Results 21 to 30 of about 152,744 (302)
Protein Phosphatase 1H, Cyclin-Dependent Kinase Inhibitor p27, and Cyclin-Dependent Kinase 2 in Paclitaxel Resistance for Triple Negative Breast Cancers. [PDF]
J Breast Cancer, 2020 Paclitaxel is a cytotoxic chemotherapy commonly used in patients with triple negative breast cancer (TNBC); however, the resistance to paclitaxel is a cause of poor response in the patients. The aim of this study was to examine the role of protein phosphatase 1H (PPM1H) in paclitaxel resistance in breast cancer patients.To investigate the function of ...
Hur S +12 more
europepmc +5 more sources
A novel binding pocket of cyclin‐dependent kinase 2 [PDF]
Proteins: Structure, Function, and Bioinformatics, 2008 AbstractThe cyclin‐dependent kinase 2 (cdk2) is a serine/threonine protein kinase that plays a key role in the cell cycle control system of all eukaryotic organisms. It has been a much studied drug target for potential anticancer therapy. Most cdk2 inhibitors in clinical development target almost exclusively the catalytic ATP‐binding pocket of cdk2 ...
Fatah Kashanchi +4 more
openaire +3 more sources
Binding Study of Naringenin Derivatives and Cyclin Dependent Kinase 2 [PDF]
Bulletin of the Korean Chemical Society, 2007 Among several classes ofphenolic compounds, a group with the core structure of C6-C3-C6 is named flavonoids (benzo-γ-pyran derivatives),consisting of phenolic and pyran rings. According to theoxidation state of pyran ring, flavonoids can be furthersubdivided into five major subclasses as follows: flavonols,flavanols, flavones, isoflavones, and ...
Ho Jung Kim +8 more
openalex +4 more sources
Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma. [PDF]
Mol Med Rep, 2015 Cyclin-dependent kinase 2 (CDK2) has been reported to be overexpressed in human colorectal cancer; it is responsible for the G1‑to‑S‑phase transition in the cell cycle and its deregulation is a hallmark of cancer. The present study was the first to use idock, a free and open‑source protein‑ligand docking software developed by our group, to identify ...
Shi XN +7 more
europepmc +5 more sources
A Simple and Efficient Docking Method to the Cyclin-Dependent Kinase 2 [PDF]
Bulletin of the Korean Chemical Society, 2007 The subtle but significant differences and thereby the lack of consensus in active site structures among the crystal structures of cyclin-dependent kinase 2 (CDK2) has hampered structure-based drug design. In this study, we devised a simple but effective ‘mutation, pharmacophore-guided docking, followed by mutation' strategy to generate an “average ...
Kwang‐Su Park +3 more
openalex +4 more sources
Scientific Reports, 2021 S-phase kinase associated protein 2 (Skp2), a member of the F-box family that constitute the largest known class of ubiquitin E3 specificity components, is responsible for recognizing and recruiting cyclin-dependent kinase inhibitor p27 for its ...
Kaizhao Hu +4 more
doaj +1 more source
Toxicology Reports, 2015 Cell cycle deregulation is common in human hepatocellular carcinoma (HCC). To ensure proper cell cycle controlling, cyclin/cyclin-dependent kinases (CDK) complexes are tightly regulated by CDK inhibitors (CKIs) in normal cells.
Yu-Ting Peng +9 more
doaj +1 more source
Optimization of luminescent assay for screening of cyclin-dependent kinase 2 inhibitors [PDF]
Indian Journal of Pharmaceutical Sciences, 2010 Cyclin-dependent kinases are most extensively studied targets for cancer chemotherapy since the tumor cells exhibit false checkpoints and can proliferate even if the genome is compromised. Cyclin-dependent kinases ensure the tight regulation of the cell cycle execution by mediating phosphorylation of cellular proteins.
M P Suthar, M M Patel
openaire +3 more sources
Brazilian Journal of Medical and Biological Research, 2014 p15INK4B, a cyclin-dependent kinase inhibitor, has been recognized as a tumor suppressor. Loss of or methylation of the p15INK4B gene in chronic myeloid leukemia (CML) cells enhances myeloid progenitor formation from common myeloid progenitors. Therefore,
D.Y. Xia +5 more
doaj +1 more source
Break CDK2/Cyclin E1 interface allosterically with small peptides. [PDF]
PLoS ONE, 2014 Most inhibitors of Cyclin-dependent kinase 2 (CDK2) target its ATP-binding pocket. It is difficult, however, to use this pocket to design very specific inhibitors because this catalytic pocket is highly conserved in the protein family of CDKs.
Hao Chen +9 more
doaj +1 more source